REG - Aptamer Group PLC - Posting of Annual Report and Notice of AGM

AptamerAnnouncement

20/11/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231120:nRST9030Ta&default-theme=true

RNS Number : 9030T  Aptamer Group PLC  20 November 2023

20 November 2023

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Posting of Annual Report and Accounts and Notice of Annual General Meeting

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, today announces that the
Annual Report and Accounts for the year ended 30 June 2023 and Notice of its
2023 Annual General Meeting (AGM) were posted to shareholders today.  These
documents are available on the company's website at https://aptamergroup.com/.

Aptamer will host its AGM at 10:00 GMT on 15 December 2023 at Windmill House,
Innovation Way, York, YO10 5BR.  The AGM will be held in person only and
there will be no new information presented at the meeting.

 

The results of voting on all resolutions at the AGM will be announced via a
Regulatory News Service and the full results of the voting will be published
on the Company's website, as soon as practicable after the conclusion of the
AGM.

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer(®)
platform.

Optimer(®) binders are oligonucleotide affinity ligands that can function as
an antibody alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer(®) binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

Aptamer has successfully delivered projects for global pharma companies,
diagnostic development companies and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer(®) technology and processes, scientists
and collaborators can make faster, more informed decisions that support
discovery and development across the Life Sciences.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAEASFNFLKDFFA